AMGN

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SVB, Amgen, and Signature and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, April 24, 2023
AMGN, P.C, ASC, IRS, Financial services, Tax, Signature, Government, Deficiency, SVB, Investment, Risk, OTC, Silicon, Signature Bank, Environment, News, DFS, Audit, Cryptocurrency, Amgen

When the true details entered the market, the lawsuit claims that investors suffered damages.

Key Points: 
  • When the true details entered the market, the lawsuit claims that investors suffered damages.
  • For more information on the SVB class action go to: https://bespc.com/cases/SIVB
    Amgen is one of the world’s largest independent biopharmaceutical companies.
  • On this news, the price of Amgen common stock fell by an additional 4.3%, further damaging investors.
  • For more information on the Signature class action go to: https://bespc.com/cases/SBNY

AMGEN ANNOUNCES WEBCAST OF 2023 FIRST QUARTER FINANCIAL RESULTS

Retrieved on: 
Friday, April 21, 2023
AMGN, Webcast, Calendar, Internet, Broadcasting, Amgen

THOUSAND OAKS, Calif., April 21, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Thursday, April 27, 2023, after the close of the U.S. financial markets.

Key Points: 
  • THOUSAND OAKS, Calif., April 21, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Thursday, April 27, 2023, after the close of the U.S. financial markets.
  • The announcement will be followed by a conference call with the investment community at 1:30 p.m. PT.
  • Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
  • Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar.

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Amgen Investors of a Lead Plaintiff Deadline of May 12, 2023

Retrieved on: 
Friday, April 21, 2023
AMGN, Vincent Wong, Law, Person, Amgen

NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- Attention Amgen Inc. ("Amgen") (NASDAQ: AMGN) shareholders:

Key Points: 
  • NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- Attention Amgen Inc. ("Amgen") (NASDAQ: AMGN) shareholders:
    The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors.
  • This lawsuit is on behalf of all persons who purchased or otherwise acquired Amgen common stock between July 29, 2020 and April 27, 2022, inclusive.
  • If you suffered a loss on your investment in Amgen, contact us about potential recovery by using the link below.
  • There is no cost or obligation to you.

ROSEN, A TOP RANKED LAW FIRM, Encourages Amgen Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AMGN

Retrieved on: 
Friday, April 21, 2023
Titan, AMGN, ASC, IRS, Class, Tax, Plaintiff, Government, Risk, Advertising, Court, I-Space (Chinese company), Insurance, Tobacco, Security (finance), Amgen

WHAT TO DO NEXT: To join the Amgen class action, go to https://rosenlegal.com/submit-form/?case_id=13114 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Amgen class action, go to https://rosenlegal.com/submit-form/?case_id=13114 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amgen Inc. (AMGN)

Retrieved on: 
Friday, April 21, 2023
AMGN, ASC, IRS, Tax, Government, Suite, Risk, Court, Defendant, GPM, News, Cryptocurrency, Amgen

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On this news, Amgen’s stock price fell $15.77, or 6.5%, to close at $228.31 per share on August 4, 2021, thereby injuring investors.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

SHAREHOLDER ALERT: The Gross Law Firm Reminds Shareholders of Amgen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 12, 2023 – (NASDAQ: AMGN)

Retrieved on: 
Thursday, April 20, 2023
AMGN, Amgen, Average revenue per user, Internal Revenue Service, Tax, Person, Government, Risk, CLASS, NEXT, Accounting Standards Codification, Fraud, Holding company, Security (finance)

CLASS PERIOD: This lawsuit is on behalf of all persons who purchased or otherwise acquired Amgen common stock between July 29, 2020 and April 27, 2022, inclusive.

Key Points: 
  • CLASS PERIOD: This lawsuit is on behalf of all persons who purchased or otherwise acquired Amgen common stock between July 29, 2020 and April 27, 2022, inclusive.
  • DEADLINE: May 12, 2023 Shareholders should not delay in registering for this class action.
  • The Gross Law Firm is nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Amgen Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AMGN

Retrieved on: 
Wednesday, April 19, 2023
Titan, AMGN, ASC, IRS, Class, Tax, Government, Risk, Advertising, Court, I-Space (Chinese company), Insurance, Tobacco, Security (finance), Amgen

WHAT TO DO NEXT: To join the Amgen class action, go to https://rosenlegal.com/submit-form/?case_id=13114 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Amgen class action, go to https://rosenlegal.com/submit-form/?case_id=13114 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

AMGEN WINS PATENT APPEAL ON OTEZLA® (APREMILAST)

Retrieved on: 
Wednesday, April 19, 2023
Apremilast, AMGN, Patent, Amgen, United States Court of Appeals for the Federal Circuit, Judgement, Psoriasis, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., Light, District court, Patient, Zydus Lifesciences, Douglas v. U.S. District Court ex rel Talk America, Generic drug, Novartis

THOUSAND OAKS, Calif., April 19, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for the District of New Jersey in a patent infringement lawsuit against Sandoz Inc. ("Sandoz") and Zydus Pharmaceuticals (USA), Inc. ("Zydus"). Today's decision affirms the permanent injunction entered by the district court prohibiting Sandoz and Zydus from making, using, selling, offering to sell, or importing each of their generic versions of Otezla until February 2028.

Key Points: 
  • Three of Amgen's patents were the subject of the appeal.
  • The appellate court upheld the validity of U.S. Patent No.
  • 7,427,638, which claims pharmaceutical compositions of apremilast, and U.S. Patent No.
  • Before trial, both Sandoz and Zydus acknowledged that their generic versions of Otezla infringe the asserted claims of U.S. Patent No.

AMGN ALERT: The Klein Law Firm Reminds Investors of a Lead Plaintiff Deadline of May 12, 2023 in the Class Action Filed on Behalf of Amgen Inc. Shareholders

Retrieved on: 
Wednesday, April 19, 2023
Average revenue per user, Internal Revenue Service, Telephone, COST, Tax, HOW, Person, Government, Risk, CLASS, Accounting Standards Codification, AMGN, Amgen

NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Amgen Inc. (NASDAQ: AMGN) alleging that the Company violated federal securities laws.

Key Points: 
  • NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Amgen Inc. (NASDAQ: AMGN) alleging that the Company violated federal securities laws.
  • This lawsuit is on behalf of all persons who purchased or otherwise acquired Amgen common stock between July 29, 2020 and April 27, 2022, inclusive.
  • Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
  • HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the AMGN lawsuit, please contact J. Klein, Esq.

AMGN LAWSUIT ALERT: Levi & Korsinsky Reminds Amgen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Tuesday, April 18, 2023
AMGN, CASE, LLP, Average revenue per user, Internal Revenue Service, Telephone, COST, Tax, Person, Government, Levi, Risk, CLASS, NEXT, Court, Accounting Standards Codification, Cryptocurrency, Insurance, Amgen

NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Amgen investors who were adversely affected by alleged securities fraud.
  • This lawsuit is on behalf of all persons who purchased or otherwise acquired Amgen common stock between July 29, 2020 and April 27, 2022, inclusive.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.